BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31972992)

  • 1. Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA.
    Campillo-Davo D; Versteven M; Roex G; Reu H; Heijden SV; Anguille S; Berneman ZN; Tendeloo VFIV; Lion E
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31972992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity.
    Morimoto S; Fujiki F; Kondo K; Nakajima H; Kobayashi Y; Inatome M; Aoyama N; Nishida Y; Tsuboi A; Oka Y; Nishida S; Nakata J; Hosen N; Oji Y; Sugiyama H
    Oncotarget; 2018 Sep; 9(75):34132-34141. PubMed ID: 30344927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
    Jaigirdar A; Rosenberg SA; Parkhurst M
    J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells.
    Kondo K; Fujiki F; Nakajima H; Yatsukawa E; Morimoto S; Tatsumi N; Nishida S; Nakata J; Oka Y; Tsuboi A; Hosen N; Oji Y; Sugiyama H
    J Immunother; 2016 Apr; 39(3):127-39. PubMed ID: 26938946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.
    Fujiki F; Morimoto S; Nishida Y; Tanii S; Aoyama N; Inatome M; Inoue K; Katsuhara A; Nakajima H; Nakata J; Nishida S; Tsuboi A; Oka Y; Oji Y; Sogo S; Sugiyama H
    Cancer Immunol Immunother; 2023 Jul; 72(7):2347-2356. PubMed ID: 36939853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avidity characterization of genetically engineered T-cells with novel and established approaches.
    Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
    BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers.
    Walseng E; Wang B; Yang C; Patel P; Zhao C; Zhang H; Zhao P; Mazor Y
    Front Immunol; 2023; 14():1275304. PubMed ID: 38022650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.
    Asai H; Fujiwara H; An J; Ochi T; Miyazaki Y; Nagai K; Okamoto S; Mineno J; Kuzushima K; Shiku H; Inoue H; Yasukawa M
    PLoS One; 2013; 8(2):e56820. PubMed ID: 23441216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.
    Ruggiero E; Carnevale E; Prodeus A; Magnani ZI; Camisa B; Merelli I; Politano C; Stasi L; Potenza A; Cianciotti BC; Manfredi F; Di Bono M; Vago L; Tassara M; Mastaglio S; Ponzoni M; Sanvito F; Liu D; Balwani I; Galli R; Genua M; Ostuni R; Doglio M; O'Connell D; Dutta I; Yazinski SA; McKee M; Arredouani MS; Schultes B; Ciceri F; Bonini C
    Sci Transl Med; 2022 Feb; 14(631):eabg8027. PubMed ID: 35138911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
    Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
    Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.
    Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR
    J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
    Li Q; Hu W; Liao B; Song C; Li L
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fast and robust method to clone and functionally validate T-cell receptors.
    Birkholz K; Hofmann C; Hoyer S; Schulz B; Harrer T; Kämpgen E; Schuler G; Dörrie J; Schaft N
    J Immunol Methods; 2009 Jul; 346(1-2):45-54. PubMed ID: 19427315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.
    Tamanaka T; Oka Y; Fujiki F; Tsuboi A; Katsuhara A; Nakajima H; Hosen N; Nishida S; Lin YH; Tachino S; Akatsuka Y; Kuzushima K; Oji Y; Kumanogoh A; Sugiyama H
    Anticancer Res; 2012 Dec; 32(12):5201-9. PubMed ID: 23225417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.
    Van den Bosch GA; Ponsaerts P; Nijs G; Lenjou M; Vanham G; Van Bockstaele DR; Berneman ZN; Van Tendeloo VF
    Clin Exp Immunol; 2005 Mar; 139(3):458-67. PubMed ID: 15730391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.
    Lahman MC; Schmitt TM; Paulson KG; Vigneron N; Buenrostro D; Wagener FD; Voillet V; Martin L; Gottardo R; Bielas J; McElrath JM; Stirewalt DL; Pogosova-Agadjanyan EL; Yeung CC; Pierce RH; Egan DN; Bar M; Hendrie PC; Kinsella S; Vakil A; Butler J; Chaffee M; Linton J; McAfee MS; Hunter DS; Bleakley M; Rongvaux A; Van den Eynde BJ; Chapuis AG; Greenberg PD
    Sci Transl Med; 2022 Feb; 14(631):eabg8070. PubMed ID: 35138909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
    Zhao Q; Ahmed M; Tassev DV; Hasan A; Kuo TY; Guo HF; O'Reilly RJ; Cheung NK
    Leukemia; 2015 Nov; 29(11):2238-47. PubMed ID: 25987253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T cells confers killing activity against human leukemia cells.
    Katsuhara A; Fujiki F; Aoyama N; Tanii S; Morimoto S; Oka Y; Tsuboi A; Nakajima H; Kondo K; Tatsumi N; Nakata J; Nakae Y; Takashima S; Nishida S; Hosen N; Sogo S; Oji Y; Sugiyama H
    Anticancer Res; 2015 Mar; 35(3):1251-61. PubMed ID: 25750272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.